Antibodies are proteins with two arms that can recognise and bind to specific biomarkers (antigens) of pathogens or tumour cells. Bispecific antibodies are antibodies modified so each of their two arms can recognize a specific antigen. These treatments are increasingly being studied in hematology because they can stimulate the immune system by bringing it in direct contact with cancer cells.

Clinical trials are currently being conducted to evaluate the benefit of bispecific antibodies to treat patients with Non-Hodgkin B lymphoma who relapse following treatment with CAR T-cells. However, to date, there is very little data on the efficacy of CAR-T to treat patients who relapse or progress after treatment by bispecific antibodies.

This project aims to better understand the efficacy and safety of CAR-T for patients with Non-Hodgkin B lymphoma who are refractory to or relapse after bispecific antibodies. It was initiated by Gilles Crochet, hematologist at Lille University Hospital, in April 2022. The project uses data from the DESCAR-T registry with additional data from patient medical records on aspects related to previous treatment by bispecific antibodies. Statistical analyses are performed by LYSARC.

For more information about the treatment of your data in the Registry, and more specifically those with lymphoma who were treated with bispecific antibodies before receiving CAR-T, if you would like more information about the treatment of your data in the DESCAR-T Registry and for this project, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.